The number of targeted therapies and complexity of biomarker detection linked to these therapies has grown over the last decade. To accommodate it, the drug development process must also evolve. In this webinar, we will show how combining the power of molecular and immune profiling to drive molecular-based testing is improving stratification methods and patient outcomes. We will also showcase the impact of a scalable comprehensive assay and infrastructure in the context of drug development.
Chief Scientific Officerand Director Genomics Technologies,
OmniSeq Inc., Roswell Park Comprehensive Cancer Center